Motion Correction in Dynamic Contrast Enhanced MRI in Ovarian Cancer: A Pilot Study
- Patients with measurable disease with evidence of at least one uni-dimensionally
measurable tumor (> 1 cm) by CT or MRI scan according to RECIST (Response Evaluation
Criteria in Solid Tumors) that the tumor has not been initially treated with surgery
or radiation therapy.
- Patients who will start treatment with bevacizumab combined with or without cytotoxic
chemotherapy within 14 days from signing consent. Patients treated on an approved IRB
therapeutic protocol for recurrent ovarian cancer with bevacizumab are eligible.
- Patients with histologically confirmed ovarian epithelial cancer including primary
peritoneal and fallopian tube adenocarcinoma.
- Patients of childbearing potential must have a negative serum pregnancy test prior to
the study entry and be practicing an effective form of contraception.
- Patients who are older than 21 years of age.
- Patients who are able to understand and sign informed consent.
- Patients treated on an approved IRB therapeutic protocol with a blinded arm of
bevacizumab or placebo are not eligible (IRB 07-078 and IRB 05-138).
- Patients with cardiac pacemakers.
- Patients with certain prosthetic devices and implants who are not compatible with the
high magnetic field present in the DCE-MRI scanners.
- Patients who have experienced a prior adverse reaction to the gadolinium complex
contrast agent used in DCE-MRI imaging and who don't meet criteria for creatinine and
nephrogenic systemic sclerosis risk per guidelines of department of radiology.
- Patients prone to claustrophobia.
- Patients on dialysis.